WeightWatchers stock rallies 170%! But new compounded GLP-1 drug is 'not a sustainable long-term business model.'
WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence. The weight-loss company, previously championed by the likes of Oprah Winfrey, saw its stock spike this week after announcing that it will make copycats of Novo Nordisk's (NVO) Ozempic and Wegovy weight-loss drugs.
WeightWatchers Adds Compounded GLP-1, Expanding Accessibility and Affordability of Weight Loss Medications
WeightWatchers (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) announced today the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight management interventions that are underpinned by the comprehensive,
WeightWatchers Stock Soars on Copycat Weight-Loss Drug Offering
Shares of WW International, better known as WeightWatchers, soared Tuesday after it said it is offering copycat weight-loss drugs to its members.
WeightWatchers stock price skyrockets on news that it will offer a compounded GLP-1 weight-loss drug like Wegovy
The embattled diet brand said it is adding a compounded weight-loss drug in accordance with FDA rules and manufacturing standards.
WeightWatchers to offer compounded version of Wegovy weight-loss drug
WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of its weight-management programs.
WeightWatchers’ stock soars after adding compounded GLP-1 treatment to its offering
Shares of WW International Inc., known as WeightWatchers, soared 18% Tuesday, after the weight-management company announced the addition of compounded GLP-1 obesity treatments to its offering. The new offering starts at $129.
WeightWatchers to offer compounded weight-loss drugs
WeightWatchers will begin selling compounded alternatives to certain weight-loss drugs that are experiencing shortages. Why it matters: Federal law allows companies to sell compounded versions of drugs that are on the FDA's shortages list — which has led to a surge of copycats to the newly popular class of GLP-1 injections.
WeightWatchers offers version of Ozempic, despite FDA concerns
High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA say those versions come with risks.
WeightWatchers offering compounded version of Ozempic, despite concerns expressed by FDA
High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA ...
WW International: The Party Won't Last Long
WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...
What's Going With WeightWatchers Stock On Wednesday?
WeightWatchers stock rises after the company announces compounded semaglutide offerings, addressing GLP-1 shortages while ...
Compounded Semaglutide: Is It Safe and Effective?
Compounded semaglutide is semaglutide with an altered formula to create an unbranded alternative to Wegovy and Ozempic.
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...
bovnews1d
WeightWatchers (WW) Surges in Premarket Trading: A Closer Look at Recent Developments
WeightWatchers recently announced the inclusion of compounded semaglutide into its suite of offerings. This new clinical weight management intervention aims to broaden access for eligible members who ...